Highly Potent Metallopeptide Analogues of Luteinizing Hormone-Releasing Hormone
Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides t...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 86; no. 16; pp. 6313 - 6317 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
National Academy of Sciences of the United States of America
01.08.1989
National Acad Sciences |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N-ε(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1, D-Phe(pCl)2,D-Pal(3)2, Arg5, D-Lys{Dl-A2pr(Sal2Cu)}$^{6}$ , D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(Dl-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 μ g in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides. |
---|---|
AbstractList | Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and transbis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N epsilon-(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2, D-Pal(3)2, Arg5,D-Lys[DL-A2pr(Sal2Cu)]6,D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 micrograms in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides. Metal complexes related to the cytotoxic complexes cisplatin (cis-diamminedichloroplatinum(II)) and transbis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer and prostate cancer cell lines in vitro. Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides. Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and transbis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N epsilon-(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2, D-Pal(3)2, Arg5,D-Lys[DL-A2pr(Sal2Cu)]6,D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 micrograms in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and transbis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N epsilon-(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2, D-Pal(3)2, Arg5,D-Lys[DL-A2pr(Sal2Cu)]6,D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 micrograms in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides. Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N-ε(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1, D-Phe(pCl)2,D-Pal(3)2, Arg5, D-Lys{Dl-A2pr(Sal2Cu)}$^{6}$ , D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(Dl-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 μ g in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides. |
Author | Schally, A. V. Bokser, L. Fekete, M. Redding, T. W. Srkalovic, G. Csernus, V. J. Bajusz, S. Janaky, T. |
AuthorAffiliation | Endocrine Polypeptide and Cancer Institute, Veterans Administration Medical Center, New Orleans, LA |
AuthorAffiliation_xml | – name: Endocrine Polypeptide and Cancer Institute, Veterans Administration Medical Center, New Orleans, LA |
Author_xml | – sequence: 1 givenname: S. surname: Bajusz fullname: Bajusz, S. – sequence: 2 givenname: T. surname: Janaky fullname: Janaky, T. – sequence: 3 givenname: V. J. surname: Csernus fullname: Csernus, V. J. – sequence: 4 givenname: L. surname: Bokser fullname: Bokser, L. – sequence: 5 givenname: M. surname: Fekete fullname: Fekete, M. – sequence: 6 givenname: G. surname: Srkalovic fullname: Srkalovic, G. – sequence: 7 givenname: T. W. surname: Redding fullname: Redding, T. W. – sequence: 8 givenname: A. V. surname: Schally fullname: Schally, A. V. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19510858$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/2548206$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/7191552$$D View this record in Osti.gov |
BookMark | eNp9kcFrFDEYxYNU6rZ6FgRlKKin2SaTTCY5eChFXWGlInoOafbLbko2GScZsf3rzbDr0gp6CuT93peX952goxADIPSc4DnBHT3vg05zweeEzzkl9BGaESxJzZnER2iGcdPVgjXsCTpJ6QZjLFuBj9Fx0zLRYD5DVwu33vjb6kvMEHL1GbL2PvbQZ7eC6iJoH9cjpCraajlmcMHdubCuFnHYliD1V_Cg072bp-ix1T7Bs_15ir5_eP_tclEvrz5-urxY1qYlItcrSiU3oHnTWsKg1RKoJYJfS06MZNAxCoSC4MAk0dDZztqSmXR4JRumMT1F73Zz-_F6CytTwg_aq35wWz3cqqideqgEt1Hr-FM1shONLP6znT-m7FQyLoPZmBgCmKw6IknbNgV6s39kiD9KC1ltXTLgvQ4Qx6S6gpW6aQFf3k9ziLGvueiv97pORns76GBcOmBEljGiFYVrd5wZYkoDWFWC6ezi9AfnFcFq2rqatq4EV4SraevFd_6X7zD6n45X-0ST8Id-ALz9L6Ds6H2GX7mQL3bkTcpxOKCUUSLob14u0To |
CODEN | PNASA6 |
CitedBy_id | crossref_primary_10_1002_anie_201204631 crossref_primary_10_1007_s00726_010_0766_1 crossref_primary_10_1016_S1016_8478_23_13504_7 crossref_primary_10_1016_j_brainresbull_2015_11_002 crossref_primary_10_1562_0031_8655_2001_0740226GOFRBE2_0_CO2 crossref_primary_10_1016_j_ctrv_2012_12_003 crossref_primary_10_1016_j_jconrel_2016_11_002 crossref_primary_10_1016_S0163_7258_99_00018_2 crossref_primary_10_1007_s43393_021_00037_9 crossref_primary_10_1002_med_20225 crossref_primary_10_1111_j_1600_0897_2005_00350_x crossref_primary_10_1002_pros_2990230209 crossref_primary_10_1002_psc_2769 crossref_primary_10_3762_bjoc_14_226 crossref_primary_10_1007_BF01961247 crossref_primary_10_1002_pros_10259 crossref_primary_10_1007_BF01806208 crossref_primary_10_1007_BF02443499 crossref_primary_10_1007_BF00127660 crossref_primary_10_1002_zaac_19976230194 crossref_primary_10_1002_ange_201204631 crossref_primary_10_1002_pros_2990260403 crossref_primary_10_1002_psc_2775 crossref_primary_10_1007_BF01212725 crossref_primary_10_1021_jo102371q crossref_primary_10_1248_cpb_c17_00098 crossref_primary_10_1107_S1600536808016796 crossref_primary_10_1517_13543784_2011_574611 crossref_primary_10_2174_0929867325666180104153848 crossref_primary_10_3390_ijms20184421 crossref_primary_10_3109_07357909109039878 crossref_primary_10_1007_s11705_008_0023_2 crossref_primary_10_1210_er_2012_1014 crossref_primary_10_1073_pnas_96_20_11081 crossref_primary_10_1562_0031_8655_2001_074_0226_GOFRBE_2_0_CO_2 crossref_primary_10_3390_pharmaceutics13091433 crossref_primary_10_1107_S1600536808007228 crossref_primary_10_1016_j_brainresbull_2020_01_005 crossref_primary_10_1039_C2DT31782F crossref_primary_10_3762_bjoc_14_64 |
ContentType | Journal Article |
Copyright | 1991 INIST-CNRS |
Copyright_xml | – notice: 1991 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 OTOTI 5PM |
DOI | 10.1073/pnas.86.16.6313 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic OSTI.GOV PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) |
EISSN | 1091-6490 |
EndPage | 6317 |
ExternalDocumentID | PMC297829 7191552 2548206 19510858 10_1073_pnas_86_16_6313 86_16_6313 34318 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, U.S. Gov't, P.H.S Comparative Study Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA40003 – fundername: NCI NIH HHS grantid: CA40004 |
GroupedDBID | --- -DZ -~X .55 .GJ 0R~ 123 29P 2AX 2FS 2WC 3O- 4.4 53G 5RE 5VS 85S AACGO AAFWJ AANCE ABBHK ABOCM ABPLY ABPPZ ABTLG ABXSQ ABZEH ACGOD ACHIC ACIWK ACNCT ACPRK ADQXQ ADULT ADXHL AENEX AEUPB AEXZC AFFNX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS AQVQM AS~ CS3 D0L DCCCD DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 HGD HH5 HQ3 HTVGU HYE IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST KQ8 L7B LU7 MVM N9A NEJ N~3 O9- OK1 P-O PNE PQQKQ R.V RHI RNA RNS RPM RXW SA0 SJN TN5 UKR VOH W8F WH7 WHG WOQ WOW X7M XSW Y6R ZCA ZCG ~02 ~KM - 02 08R 0R 1AW 55 AAPBV ABFLS ABPTK ADACO ADZLD AFDAS AJYGW AS ASUFR DNJUQ DOOOF DWIUU DZ F20 GJ JSODD KM OHM PQEST RHF VQA X XFK XHC ZA5 692 6TJ 79B AAYJJ AAYXX ACKIV AFHIN AFQQW BKOMP CITATION NHB TAE YBH YKV YSK IQODW CGR CUY CVF ECM EIF NPM VXZ YIF YIN 7X8 OTOTI 5PM |
ID | FETCH-LOGICAL-c518t-d3396cea625f14e5a9e3f186b961c94e743e13e86e491ae7f7ff254170d924a03 |
ISSN | 0027-8424 |
IngestDate | Thu Aug 21 18:24:32 EDT 2025 Thu May 18 18:19:33 EDT 2023 Fri Jul 11 04:31:14 EDT 2025 Wed Feb 19 02:35:25 EST 2025 Wed Apr 02 07:17:28 EDT 2025 Tue Jul 01 01:21:54 EDT 2025 Thu Apr 24 23:02:07 EDT 2025 Wed Nov 11 00:30:01 EST 2020 Thu May 30 08:50:26 EDT 2019 Thu May 29 08:42:33 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16 |
Keywords | Antineoplastic agent Human Hypothalamic hormone Analog Animal Gonadotropin RH Affinity Drug targeting Tumor cell Metal Complexes Platinum II Complexes |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c518t-d3396cea625f14e5a9e3f186b961c94e743e13e86e491ae7f7ff254170d924a03 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/297829 |
PMID | 2548206 |
PQID | 79151093 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | jstor_primary_34318 crossref_primary_10_1073_pnas_86_16_6313 pnas_primary_86_16_6313 pubmedcentral_primary_oai_pubmedcentral_nih_gov_297829 crossref_citationtrail_10_1073_pnas_86_16_6313 pnas_primary_86_16_6313_fulltext pascalfrancis_primary_19510858 proquest_miscellaneous_79151093 pubmed_primary_2548206 osti_scitechconnect_7191552 |
ProviderPackageCode | RNA PNE CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1989-08-01 |
PublicationDateYYYYMMDD | 1989-08-01 |
PublicationDate_xml | – month: 08 year: 1989 text: 1989-08-01 day: 01 |
PublicationDecade | 1980 |
PublicationPlace | Washington, DC |
PublicationPlace_xml | – name: Washington, DC – name: United States |
PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
PublicationTitleAlternate | Proc Natl Acad Sci U S A |
PublicationYear | 1989 |
Publisher | National Academy of Sciences of the United States of America National Acad Sciences |
Publisher_xml | – name: National Academy of Sciences of the United States of America – name: National Acad Sciences |
SSID | ssj0009580 |
Score | 1.5632154 |
Snippet | Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated... Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and transbis(salicylaldoximato)copper(II) were incorporated... Metal complexes related to the cytotoxic complexes cisplatin (cis-diamminedichloroplatinum(II)) and transbis(salicylaldoximato)copper(II) were incorporated... |
SourceID | pubmedcentral osti proquest pubmed pascalfrancis crossref pnas jstor |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 6313 |
SubjectTerms | 550201 - Biochemistry- Tracer Techniques Agonists Amino Acid Sequence AMINO ACIDS ANIMAL CELLS Animals Antineoplastic agents BASIC BIOLOGICAL SCIENCES BETA DECAY RADIOISOTOPES Biological and medical sciences BODY Breast cancer Breast Neoplasms - metabolism CARBOXYLIC ACIDS Cell growth Cell Membrane - metabolism Cell membranes CHEMICAL REACTIONS CHROMATOGRAPHY Chromatography, High Pressure Liquid Cisplatin - analogs & derivatives Cisplatin - chemical synthesis Cisplatin - pharmacology Copper - pharmacology CROSS-LINKING DAYS LIVING RADIOISOTOPES Diamino amino acids Dipeptides - chemical synthesis ELECTRON CAPTURE RADIOISOTOPES Female General aspects GLANDS Gonadotropin-Releasing Hormone - analogs & derivatives Gonadotropin-Releasing Hormone - chemical synthesis Gonadotropin-Releasing Hormone - metabolism Gonadotropin-Releasing Hormone - pharmacology GONADOTROPINS HORMONES Humans In Vitro Techniques INTERMEDIATE MASS NUCLEI IODINE 125 IODINE ISOTOPES ISOTOPES LH LIBERINS LIQUID COLUMN CHROMATOGRAPHY Luteinization Luteinizing Hormone - metabolism LYSINE MAMMARY GLANDS Medical sciences MEMBRANE PROTEINS METALLOPROTEINS Molecular Sequence Data MOLECULAR STRUCTURE Nickel NUCLEI ODD-EVEN NUCLEI ORGANIC ACIDS ORGANIC COMPOUNDS Organometallic Compounds - chemical synthesis Organometallic Compounds - pharmacology ORGANS Ovulation - drug effects PEPTIDE HORMONES Pharmacology. Drug treatments Pituitary Gland - drug effects Pituitary Gland - metabolism PITUITARY HORMONES PLATINUM COMPOUNDS POLYMERIZATION PROTEINS RADIOISOTOPES Rats RECEPTORS Receptors, LHRH - metabolism SEPARATION PROCESSES Structure-Activity Relationship TRANSITION ELEMENT COMPOUNDS Tumor cell line TUMOR CELLS Tumors |
Title | Highly Potent Metallopeptide Analogues of Luteinizing Hormone-Releasing Hormone |
URI | https://www.jstor.org/stable/34318 http://www.pnas.org/content/86/16/6313.abstract https://www.ncbi.nlm.nih.gov/pubmed/2548206 https://www.proquest.com/docview/79151093 https://www.osti.gov/biblio/7191552 https://pubmed.ncbi.nlm.nih.gov/PMC297829 |
Volume | 86 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgCGkvExsMwmDkgYehKaVuHMd5HAhUTVD2sEl7i1zH1gosqZb0pX89d7Hz1a0S8BJFdmJHvsv57vy7O0LeUy1g2wizYE6FCphhJpAyC4Ox0NpIoURU5y34PuPTK3Z-HV13cNs6uqSaj9T6wbiS_6EqtAFdMUr2HyjbDgoNcA_0hStQGK5_RWMEaaB3oqjwRP9WV3iKvkScSoanAtYvU2M14Cv0Il-s0TFwA2pqkesAy6XIstfSV1Qv2o2tbGAEs8ZveNZFoTjRUJ4GpxezXk1j-XNVrgee1XP4Huun7WDZsEj5ypZj746nPhW_SstH3zqXhMVcicYl0YQIwNbHbHB0I2ZdxmvHTn2hyUMbjnpPmoP4wRLEuSxHgo8oH20-CeRY3tbEBTsXM9F3u1qLNXQ9j8mTCVgSNfZz2s_LLGyUkvviJvtTHH7cmHeXPHVDDVQYi2KFDb0AkYzIWlnCz2VsVRTMmAujPGS9bIJwe1rN5TOy58wR_8zy1j55pPMDst9Q1T9xWck_PCc_LLP5ltn8IbP5LbP5hfF7zObfY7am5QW5-vrl8vM0cNU4AhVRUQVZGCZcaQkGs6FMRzLRoaGCzxNOVcI0qKKahlpwzRIqdWxiY2DBaDzOwMaX4_CQ7OQw_CviKyoyPWF8EhvGuKSSZSwaa0w-KMdKJR4ZNQucKpeqHium_E5ryEQcpriqqeAp5SnSxiMn7QtLm6Vl-6MHNcXa50JQoYVHjpB-KaidmDtZIchMVWlMsXzCxCPHA7J2c6B9IiJ4_WU9TdPen87f0pMah-7yyLuGO1KQ7XhgJ3NdrMo0htkx3ZtHDi2vtMM4TvQIHzBR249J44c9-eKmTh4_ScAmSF5vG_GI7HZ_9BuyU92t9FtQu6v5cf3j_AFwvtgn |
linkProvider | ABC ChemistRy |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Highly+potent+metallopeptide+analogues+of+luteinizing+hormone-releasing+hormone&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Bajusz%2C+S&rft.au=Janaky%2C+T&rft.au=Csernus%2C+V+J&rft.au=Bokser%2C+L&rft.date=1989-08-01&rft.issn=0027-8424&rft.volume=86&rft.issue=16&rft.spage=6313&rft_id=info:doi/10.1073%2Fpnas.86.16.6313&rft_id=info%3Apmid%2F2548206&rft.externalDocID=2548206 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F86%2F16.cover.gif |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F86%2F16.cover.gif |